Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Tzouvelekis (Athens, Greece). Efficacy and safety of pirfenidone in patients with IPF. A single center real-life experience.. 4886

Member's Comments

No comment yet.

Related content which might interest you: Tolerability and efficacy of Pirfenidone and Nintedanib for patients with IPF in real world clinical practice Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Safety and tolerability of immunosuppression in non-IPF ILD: clinical experience from a tertiary ILD centre. Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Real-life experience with pirfenidone in idiopathic pulmonary fibrosis (IPF) in a single centre in Italy. A retrospective study. Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 Efficacy and safety of nintedanib in the elderly patient with IPF Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Budesonide/formoterol improves the wellbeing of patients with COPD: results from a real-life setting Source: Eur Respir J 2005; 26: Suppl. 49, 289s Year: 2005 Physician assessment of asthma control in patients receiving omalizumab in a real-world setting Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Characteristics of patients receiving mepolizumab in real-world practice –REALITI-A study Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 Efficacy and safety of Mepolizumab in a real world severe asthma cohort. Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Real-life data on the safety and tolerability of Pirfenidone versus Nintedanib in Idiopathic Pulmonary Fibrosis (IPF) patients: A single-centre retrospective study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Late Breaking Abstract - Effectiveness and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) from a large Italian practice cohort Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Flunisolide HFA demonstrates long-term safety vs two comparator drugs in the paediatric setting Source: Eur Respir J 2001; 18: Suppl. 33, 289s Year: 2001 Efficacy and safety of combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Safety and feasibility of tight glycaemic control for COPD patients with exacerbations on the acute medical unit. Results of a phase IIa clinical trial Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis Source: Eur Respir Rev 2015; 24: 58-64 Year: 2015 Do patients with cystic fibrosis participating in clinical trials demonstrate placebo response ? A meta-analysis. Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis Year: 2019 A real life multicenter national study on the use of nintedanib in moderate to severe IPF patients Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 314s Year: 2006 Real-world study to evaluate the safety and effectiveness of fluticasone propionate/formoterol (FP/FORM) in patients with asthma Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Efficacy and tolerability of nintedanib switched from pirfenidone for IPF patients Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice Source: ERJ Open Res, 4 (4) 00049-2018; 10.1183/23120541.00049-2018 Year: 2018